J9集团

Gastric cancer (GC) is one of the most common malignancies and is the leading global cause of death by cancer. Over recent decades, targeted therapies and immunotherapy have become significant new approaches for the treatment of GC. Ferroptosis is a newly verified form of modulated cell death that is characterized by lipid peroxidation. Further exploration of the function of ferroptosis in the progression of GC has provided novel opportunities for diagnosis and treatment. The overexpression of MGST1 induced the activation of the Akt/GSK-3β pathway. An Akt inhibitor antagonized the inhibitory effects of MGST1 on autophagy and ferroptosis. MGST1 and ATG16L1 overexpression, and MGST1 depletion assay were conducted by Medicilon.

Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in the initiation of DNA replication. TAK-931, a highly specific CDC7 inhibitor, acts as a next-generation of replication stress (RS) inducer. Combination treatment with TAK-931 and immune checkpoint inhibitors (ICIs) enhances antiproliferative activities in preclinical syngeneic mouse models. The flowcytometry (FCM)-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon. Therapeutic potential of TAK-931 in antitumor efficacy and immunity, which may improve clinical benefit of the currently-used immunotherapy by combination treatment.

Chrysin is a natural flavonoid that has been reported as a potential treatment for non-alcoholic fatty liver disease (NAFLD). Researchers synthesized a novel chrysin derivative prodrug (C-1) and further investigated its potential therapeutic mechanism against NAFLD in vitro and in vivo. C-1 had a low toxicity profile. Their data demonstrated that C-1 may be a promising agent for NAFLD therapy. Evaluation experiments of the acute toxicities of C-1 were conducted by Medicilon.

?J9集团作为领诺医药的合作同伴
，为SLN12140提供了体表药效、药代、安评等一站式临床前研发服务
，为该药物尽早进入临床阶段奠定了坚实基础。

J9集团作为清普生物合作同伴
，为美洛昔康注射液（Ⅱ）提供了部门关键临床前研发服务
，为其急剧获批上市奠定基础。

J9集团作为菌济健全合作同伴
，为LBP-ShC4提供了体内药效、药代、安评等临床前研发服务
，助力该项目突破传统研发瓶颈
，降低研发成本
，加快临床转化过程。

J9集团作为祐森健恒的合作同伴
，为UA026的临床前研发提供了药代动力学、安全性评价服务
，以专业高效的技术
，为该药急剧获批临床奠定了坚实基础。

J9集团作为核新生物的合作同伴
，为XY003的临床前研发提供了CMC钻研（蕴含原料药和造剂）服务
，并获颁“2024年度卓越合作同伴奖”和感激信
，其高效研发服务和专业创新能力获核新生物高度注定。

J9集团作为海擘生物合作同伴
，为NC527-X提供了CMC研发（原料药、造剂）、临床前研发（药效、药代、安评）以及注册申报等一站式临床前综合研发服务。这也是J9集团又一个提供全套IND申报服务的成功案例！

J9集团作为银珠医药的合作同伴
，依附肺癌骨转移模型药效评价模型
，为幼分子免疫抑造剂YZ008的研发提供了药效服务
，加快了新药研发过程
，为这次合作奠定了坚实基础。